AP-238 is an opioid designer drug related to drugs such as azaprocin and bucinnazine, with around the same potency as morphine.[2] It was first discovered in Italy in the 1960s but was never marketed,[3] subsequently appearing on the illicit market around 2020 and being detected in both Slovenia and the USA.[4][5]
![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C18H26N2O |
Molar mass | 286.419 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
editReferences
edit- ^ "2-Methyl-AP-237" (PDF). Office of Diversion Control. U.S Drug Enforcement Administration.
- ^ Fogarty MF, Vandeputte MM, Krotulski AJ, Papsun D, Walton SE, Stove CP, Logan BK (June 2022). "Toxicological and pharmacological characterization of novel cinnamylpiperazine synthetic opioids in humans and in vitro including 2-methyl AP-237 and AP-238". Archives of Toxicology. 96 (6): 1701–1710. doi:10.1007/s00204-022-03257-7. PMID 35275255. S2CID 247383361.
- ^ Cignarella G, Testa E (May 1968). "2,6-Dialkylpiperazines. IV. 1-Propionyl-4-substituted cis-2,6-dimethylpiperazines structurally related to the analgetic 8-acyl-3,8-diazabicyclo[3.2.1]octanes". Journal of Medicinal Chemistry. 11 (3): 592–594. doi:10.1021/jm00309a039. PMID 5656502.
- ^ {{cite web | url = https://www.policija.si/apps/nfl_response_web/0_Analytical_Reports_final/AP-238-ID-2185-20_report.pdf | title = Analytical Report. AP-238. 1-{2,6‐dimethyl‐4‐[(2E)‐3‐phenylprop‐2‐en‐1‐yl]piperazin‐1‐yl}propan-1-one. | work =Nacionalni Forenzični Laboratorij | date = 20 October 2020 }}
- ^ "AP-238" (PDF). NPS Discovery at CFSRE. Center for Forensic Science Research and Education (CFSRE). 11 November 2020.